Insulin

Verify with FDA CVM →

1,053 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
1,053
Total Reports
165
Deaths Reported
1570.0%
Death Rate

Active Ingredients

Insulin

Administration Routes

UnknownSubcutaneousParenteralIntravenousIntramuscularSubconjunctivalOtherOralTopicalCutaneous

Species Affected

Dog 737
Cat 311
Human 4
Unknown 1

Most Affected Breeds

Domestic Shorthair 217
Retriever - Labrador 64
Chihuahua 54
Terrier - Yorkshire 40
Schnauzer - Miniature 39
Shih Tzu 32
Pug 29
Pinscher - Miniature 28
Maltese 28
Dog (unknown) 27

Most Reported Reactions

Hyperglycaemia 240
Vomiting 185
Lethargy (see also Central nervous system depression in 'Neurological') 141
Weight loss 115
Other abnormal test result NOS 107
Hypoglycaemia 106
Anorexia 101
Death by euthanasia 95
Diarrhoea 95
Elevated alanine aminotransferase (ALT) 84
Not eating 78
Decreased appetite 72

Outcome Breakdown

Ongoing
371 (35.4%)
Outcome Unknown
326 (31.1%)
Recovered/Normal
170 (16.2%)
Euthanized
91 (8.7%)
Died
74 (7.1%)
Recovered with Sequela
17 (1.6%)

Data Summary

Metric Value
Total adverse event reports 1,053
Reports involving death 165
Case-fatality rate (reported events) 1570.0%
Distinct species in reports 4
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Insulin Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 1,053 adverse event reports referencing Insulin, including 165 reports in which the animal died — a 1570.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Insulin. Reported administration routes include Unknown, Subcutaneous, Parenteral, Intravenous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Insulin reports are Dog (737 reports), Cat (311 reports), Human (4 reports), with Dog accounting for the largest share. Within those species, Domestic Shorthair (217), Retriever - Labrador (64), Chihuahua (54) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Insulin are Hyperglycaemia (240), Vomiting (185), Lethargy (see also Central nervous system depression in 'Neurological') (141), Weight loss (115). Of the 1,049 reports with a coded outcome, Ongoing is the leading category at 35.4%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Insulin.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial